Novel investigational therapies for treating biliary tract carcinoma

References

• Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383(9935):2168–2179. .
   PubMed Web of Science ®Google Scholar
• Alvaro D, Crocetti E, Ferretti S, et al. Descriptive epidemiology of cholangiocarcinoma in Italy. Dig Liver Dis. 2010;42(7):490–495.
   PubMedGoogle Scholar
• Valle J, Wasan H, Palmer DH, et al. ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–1281.
   PubMed Web of Science ®Google Scholar
• Pignochino Y, Sarotto I, Peraldo-Neia C, et al. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer. 2010;(10):631.
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Van Cutsem E, Rougier P, et al. Addition of cetuximab tochemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer. 2012;48(10):1466–1475.
   PubMed Web of Science ®Google Scholar
• Ye LC, Liu TS, Ren L, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol. 2013;31(16):1931–1938.
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21–28.
   PubMed Web of Science ®Google Scholar
• Chang PY, Cheng MF, Lee HS, et al. Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer. Onkologie. 2010;33(1–2):45–47.
   PubMedGoogle Scholar
• Borbath I, Ceratti A, Verslype C, et al. Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology. Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology. Ann Oncol. 2013;24(11):2824–2829.
   PubMed Web of Science ®Google Scholar
• Malka D, Cervera P, Foulon S, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. BINGO investigators. Lancet Oncol. 2014;15(8):819–828.
   PubMed Web of Science ®Google Scholar
• Paule B, Herelle MO, Rage E, et al. Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas. Oncology. 2007;72(1–2):105–110.
   PubMed Web of Science ®Google Scholar
• Gruenberger B, Schueller J, Heubrandtner U, et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol. 2010;11(12):1142–1148.
   PubMed Web of Science ®Google Scholar
• Chen JS, Hsu C, Chiang NJ, et al. A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer. Ann Oncol. 2015;26(5):943–949.
   PubMed Web of Science ®Google Scholar
• Douillard JY, Siena S, Cassidy J, et al. Results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol. 2014;25(7):1346–1355.
   PubMed Web of Science ®Google Scholar
• Jensen LH, Lindebjerg J, Ploen J, et al. Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer. Ann Oncol. 2012;23(9):2341–2346.
   PubMed Web of Science ®Google Scholar
• Hezel AF, Noel MS, Allen JN, et al. Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer. Br J Cancer. 2014;111(3):430–436.
   PubMed Web of Science ®Google Scholar
• Sohal DP, Mykulowycz K, Uehara T, et al. A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma. Ann Oncol. 2013;24(12):3061–3065.
   PubMed Web of Science ®Google Scholar
• Leone F, Marino D, Cereda S, et al. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study). Cancer. 2016;122(4):574–581.
   PubMed Web of Science ®Google Scholar
• Wu YL, Zhou C, Liam CK, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 2015;26(9):1883–1889.
   PubMed Web of Science ®Google Scholar
• Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol. 2006;24(19):3069–3074.
   PubMed Web of Science ®Google Scholar
• Lee J, Park SH, Chang HM, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012;13(2):181–188.
   PubMed Web of Science ®Google Scholar
• Lubner SJ, Mahoney MR, Kolesar JL, et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol. 2010;28(21):3491–3497.
   PubMed Web of Science ®Google Scholar
• Schramm A, De Gregorio N, Widschwendter P, et al. Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review. Breast Care (Basel). 2015;10(3):173–178.
   PubMed Web of Science ®Google Scholar
• Pectasides E. Genomic alterations and targeted therapy in gastric and esophageal adenocarcinoma. Clin Ther 2016;38(7):1589–1599.
   Google Scholar
• Yoshikawa D, Ojima H, Iwasaki M, et al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer. 2008;98(2):418–425.
   PubMed Web of Science ®Google Scholar
• Andersen JB, Spee B, Blechacz BR, et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology. 2012;142(4):1021–1031.
   PubMed Web of Science ®Google Scholar
• Law LY. Dramatic response to trastuzumab and paclitaxel in a patient with human epidermal growth factor receptor 2-positive metastatic cholangiocarcinoma. J Clin Oncol. 2012;30(27):e271–273.
   PubMed Web of Science ®Google Scholar
• Sorscher S. Marked radiographic response of a HER-2-overexpressing biliary cancer to trastuzumab. Cancer Manag Res. 2013;11(9):1–3.
   Google Scholar
• Javle M, Churi C, Kang HC, et al. HER2/neu-directed therapy for biliary tract cancer. J Hematol Oncol. 2015;29(8):58.
   Web of Science ®Google Scholar
• Peck J, Wei L, Zalupski M, et al. HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib. Oncology. 2012;82(3):175–179.
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, Belani CP, Singh DA, et al. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol. 2009;64(4):777–783.
   PubMed Web of Science ®Google Scholar
• Chung JY, Hong SM, Choi BY, et al. The expression of phospho-AKT, phosphomTOR, and PTEN in extrahepatic cholangiocarcinoma. Clin Cancer Res. 2009;15(2):660–667.
   PubMed Web of Science ®Google Scholar
• Wu Q, Kiguchi K, Kawamoto T, et al. Therapeutic effect of rapamycin on gallbladder cancer in a transgenic mouse model. Cancer Res. 2007;67(8):3794–3800.
   PubMed Web of Science ®Google Scholar
• Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520–529.
   PubMed Web of Science ®Google Scholar
• Chambers J, Reed N, Mansoor W, et al. A phase-3 randomized trial of everolimus (RAD001) vs. placebo in advanced pancreatic NET (RADIANT-3). Regul Pept. 2010;164(1):6–7.
   Google Scholar
• Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387(10022):968–977.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116(18):4256–4265.
   PubMed Web of Science ®Google Scholar
• Buzzoni R, Pusceddu S, Bajetta E, et al. Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study. Ann Oncol. 2014;25(8):1597–1603.
   PubMed Web of Science ®Google Scholar
• Costello BA, Borad MJ, Qi Y, et al. Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors. Invest New Drugs. 2014;32(4):710–716.
   PubMed Web of Science ®Google Scholar
• Pavlidis ET, Pavlidis TE. Role of bevacizumab in colorectal cancer growth and its adverse effects: a review. World J Gastroenterol. 2013;19(31):5051–5060.
   PubMed Web of Science ®Google Scholar
• Fischer S, Gillessen S, Rothermundt C. Sequence of treatment in locally advanced and metastatic renal cell carcinoma. Transl Androl Urol. 2015;4(3):310–325.
   PubMedGoogle Scholar
• Mallick S, Gandhi AK, Rath GK. Therapeutic approach beyond conventional temozolomide for newly diagnosed glioblastoma: review of the present evidence and future direction. Indian J Med Paediatr Oncol. 2015;36(4):229–237.
   PubMedGoogle Scholar
• McClung EC, Wenham RM. Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives. Int J Womens Health. 2016;15(8):59–75.
   Google Scholar
• Zhu AX, Meyerhardt JA, Blaszkowsky LS, et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol. 2010;11(1):48–54.
   PubMed Web of Science ®Google Scholar
• Guion-Dusserre JF, Lorgis V, Vincent J, et al. FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma. World J Gastroenterol. 2015;21(7):2096–2101.
   PubMed Web of Science ®Google Scholar
• Rohrberg KS, Olesen RK, Pfeiffer P, et al. Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers. ActaOncol. 2012;51(2):234–242.
   Google Scholar
• Aprile G, Rijavec E, Fontanella C, et al. Ramucirumab: preclinical research and clinical development. Onco Targets Ther. 2014;29(7):1997–2006.
   Web of Science ®Google Scholar
• Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 2005;65(10):4389–4400.
   PubMed Web of Science ®Google Scholar
• Drevs J, Siegert P, Medinger M, et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. Clin Oncol. 2007;25(21):3045–3054.
   Web of Science ®Google Scholar
• Valle JW, Wasan H, Lopes A, et al. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. Lancet Oncol. 2015;16(8):967–978.
   PubMed Web of Science ®Google Scholar
• Strumberg D, Scheulen ME, Schultheis B, et al. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer. 2012;106(11):1722–1727.
   PubMed Web of Science ®Google Scholar
• Grothey A, Van Cutsem E, Sobrero A, et al. CORRECT study group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an International, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–312.
   PubMed Web of Science ®Google Scholar
• Schlachterman A, Ww C Jr, Hilgenfeldt E, et al. Current and future treatments for hepatocellular carcinoma. World J Gastroenterol. 2015;21(28):8478–8491.
   PubMed Web of Science ®Google Scholar
• Mn F, Tomshine J, Fulp WJ, et al. A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting. PLoS One. 2015;10(4):e0120877.
   Web of Science ®Google Scholar
• El-Koueiry AB, Rankin CJ, Ben-Josef E, et al. SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Invest New Drugs. 2012;30(4):1646–1651.
   PubMed Web of Science ®Google Scholar
• Carlisle B, Demko N, Freeman G, et al. Benefit, risk, and outcomes in drug development: a systematic review of sunitinib. J Natl Cancer Inst. 2015;108(1):pii:djv292.
   PubMedGoogle Scholar
• Abdel-Rahman O, Fouad M. Systemic therapy options for advanced gastrointestinal stromal tumors beyond first-line imatinib: a systematic review. Future Oncol. 2015;11(12):1829–1843.
   PubMed Web of Science ®Google Scholar
• Larkin J, Paine A, Foley G, et al. First-line treatment in the management of advanced renal cell carcinoma: systematic review and network meta-analysis. Expert Opin Pharmacother. 2015;16(13):1915–1927.
   PubMed Web of Science ®Google Scholar
• Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501–513.
   PubMed Web of Science ®Google Scholar
• Cella D, Beaumont JL. Pazopanib in the treatment of advanced renal cell carcinoma. Ther Adv Urol. 2016;8(1):61–69.
   PubMedGoogle Scholar
• Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: A phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC study 62043). J Clin Oncol. 2009;27(19):3126–3132.
   PubMed Web of Science ®Google Scholar
• Rizvi S, Yamada D, Hirsova P, et al. A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma. J Biol Chem. 2016;291(15):8031–8047.
   PubMed Web of Science ®Google Scholar
• Ang C. Role of the fibroblast growth factor receptor axis in cholangiocarcinoma. J Gastroenterol Hepatol. 2015;30(7):1116–1122.
   PubMed Web of Science ®Google Scholar
• Ardini E, Menichincheri M, Banfi P, et al. The ALK inhibitor NMS-E628 also potentially inhibits ROS1 and induces tumor regression in ROS-driven models [abstract]. In: Annual meeting of the American association for cancer research; Apr 6–10; Washington, DC. Philadelphia (PA): American Association for Cancer Research (AACR). Cancer Res. 2013;73(8Suppl; abstract nr 2092).
   Google Scholar
• De Braud FG, Niger M, Damian S, et al. Alka-372-001: first-in-human, phase I study of entrectinib – an oral pan-trk, ROS1, and ALK inhibitor – in patients with advanced solid tumors with relevant molecular alterations. J Clin Oncol. 2015;33(suppl;abstr 2517).
   PubMed Web of Science ®Google Scholar
• Messersmith WA, Rajeshkumar NV, Tan AC, et al. Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts. Mol Cancer Ther. 2009;8(6):1484–1493.
   PubMed Web of Science ®Google Scholar
• Vultur A, Buettner R, Kowolik C, et al. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol Cancer Ther. 2008;7(5):1185–1194.
   PubMed Web of Science ®Google Scholar
• Rabbani SA, Valentino ML, Arakelian A, et al. SKI-606 (Bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis. F Mol Cancer Ther. 2010;9(5):1147–1157.
   PubMed Web of Science ®Google Scholar
• Campone M, Bondarenko I, Brincat S, et al. Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. Ann Oncol. 2012;23(3):610–617.
   PubMed Web of Science ®Google Scholar
• Isakoff SJ, Wang D, Campone M, et al. Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study. Br J Cancer. 2014;111(11):2058–2066.
   PubMed Web of Science ®Google Scholar
• Moy B, Neven P, Lebrun F, et al. Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer. Oncologist. 2014;19(4):348–349.
   PubMed Web of Science ®Google Scholar
• Roth A, Schleyer E, Schoppmeyer K, et al. Imatinib mesylate for palliative second-line treatment of advanced biliary tract cancer: a bicentric phase II study. Onkologie. 2011;34(8–9):469–470.
   PubMedGoogle Scholar
• Davies BR, Logie A, McKay JS, et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther. 2007;6(8):2209–2219.
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Cebotaru CL, Kanarev V, et al. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol. 2010;5(10):1630–1636.
   PubMed Web of Science ®Google Scholar
• Bridgewater J, Lopes A, Beare S, et al. A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study. BMC Cancer. 2016;16(1):153.
   PubMed Web of Science ®Google Scholar
• Dienstmann R, Rodon J, Serra V, et al. Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. J Mol Cancer Ther. 2014;13(5):1021–1031.
   PubMed Web of Science ®Google Scholar
• Maira SM, Pecchi S, Huang A, et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther. 2012;11(2):317–328.
   PubMed Web of Science ®Google Scholar
• Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005;24(50):7455–7464.
   PubMed Web of Science ®Google Scholar
• Leal P, Garcia P, Sandoval A, et al. AKT/mTOR substrate P70S6K is frequently phosphorylated in gallbladder cancer tissue and cell lines. Onco Targets Ther. 2013;6:1373–1384.
   PubMed Web of Science ®Google Scholar
• Ahn DH, Li J, Wei L, et al. Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in patients with advanced biliary cancer. Sci Rep. 2015;5:12122.
   PubMed Web of Science ®Google Scholar
• Sebti SM, Hamilton AD, editors. Farnesyltransferase Inhibitors in Cancer Therapy. Totowa (NJ): Humana Press; 2001.
   Google Scholar
• Nielsen LL, Shi B, Hajian G, et al. Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models. Cancer Res. 1999;59(23):5896–5901.
   PubMed Web of Science ®Google Scholar
• Li T, Guo M, Gradishar WJ, et al. A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103). Breast Cancer Res Treat. 2012;134(1):345–352.
   PubMed Web of Science ®Google Scholar
• Schwartz G, Rowinsky EK, Rha SY, et al. A phase I, pharmacokinetic, and biologic correlative study of R115777 and trastuzumab (herceptin) in patients with advanced cancer. [Abstract] Proc Am Soc Clin Oncol. 2001;20:A–322.
   Google Scholar
• Johnson DE. The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors. Endocr Relat Cancer. 2015;22(1):T1–17.
   PubMed Web of Science ®Google Scholar
• Denlinger CS, Meropol NJ, Li T, et al. A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers. Clin Colorectal Cancer. 2014;13(2):81–86.
   PubMed Web of Science ®Google Scholar
• Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 2002;62(24):7284–7290.
   PubMed Web of Science ®Google Scholar
• Santoro A, Gebbia V, Pressiani T, et al. A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study. Ann Oncol. 2015;26(3):542–547.
   PubMed Web of Science ®Google Scholar
• Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 2005;225(1):1–26.
   PubMed Web of Science ®Google Scholar
• Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10(12):2298–2308.
   PubMed Web of Science ®Google Scholar
• Yan SB, Peek VL, Ajamie R, et al. LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. Invest New Drugs. 2013;31(4):833–844.
   PubMed Web of Science ®Google Scholar
• Weitzman SP, Cabanillas ME. The treatment landscape in thyroid cancer: a focus on cabozantinib. Cancer Manag Res. 2015;7:265–278.
   PubMed Web of Science ®Google Scholar
• Lindauer M, Hochhaus A. Dasatinib. Recent Results Cancer Res. 2014;201:27–65.
   PubMedGoogle Scholar
• Montero JC, Seoane S, Ocaña A, et al. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res. 2011;17(17):5546–5552.
   PubMed Web of Science ®Google Scholar
• Park SI, Zhang J, Phillips KA, et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res. 2008;68(9):3323–3333.
   PubMed Web of Science ®Google Scholar
• Veeck J, Dahl E. Targeting the Wnt pathway in cancer: the emerging role of Dickkopf-3. Biochim Biophys Acta. 2012;1825(1):18–28.
   PubMed Web of Science ®Google Scholar
• Chen J1, Li H, Chen H, et al. Dickkopf-1 inhibits the invasive activity of melanoma cells. Clin Exp Dermatol. 2012;37(4):404–410.
   PubMed Web of Science ®Google Scholar
• Liu FZ, He L, Wang JS, et al. Effect of decitabine on DKK1 gene demethylation in leukemia cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016;24(1):56–60.
   PubMedGoogle Scholar
• Rachner TD, Göbel A, Thiele S, et al. Dickkopf-1 is regulated by the mevalonate pathway in breast cancer. Breast Cancer Res. 2014;16(1):R20.
   PubMed Web of Science ®Google Scholar
• Eads JR, Goyal L, Stein S, et al. Phase I study of DKN-01, an anti-DKK1 antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) with advanced biliary cancer. J Clin Oncol. 2016;34(suppl;abstr e15603).
   PubMed Web of Science ®Google Scholar
• Green TP, Fennell M, Whittaker R, et al. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol. 2009;3(3):248–261.
   PubMed Web of Science ®Google Scholar
• Wang L, Yu X, Dong J, et al. Combined SRC inhibitor saracatinib and anti-ErbB2 antibody H2-18 produces a synergistic antitumor effect on trastuzumab-resistant breast cancer. Biochem Biophys Res Commun. 2016;479(3):563–570.
   Google Scholar
• Jain S, Wang X, Chang CC, et al. Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer. Cancer Res. 2015;75(22):4863–4875.
   PubMed Web of Science ®Google Scholar
• Baselga J, Cervantes A, Martinelli E, et al. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. Clin Cancer Res. 2010;16(19):4876–4883.
   PubMed Web of Science ®Google Scholar
• Reddy SM, Kopetz S, Morris J, et al. Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. Invest New Drugs. 2015;33(4):977–984.
   PubMed Web of Science ®Google Scholar
• Gubens MA, Burns M, Perkins SM, et al. A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies. Lung Cancer. 2015;89(1):57–60.
   PubMed Web of Science ®Google Scholar
• Trarbach T, Schultheis B, Gauler TC, et al. Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours. Invest New Drugs. 2012;30(5):1962–1971.
   PubMed Web of Science ®Google Scholar
• Rieger-Christ KM, Lee P, Zagha R, et al. Novel expression of N-cadherin elicits in vitro bladder cell invasion via the akt signalling pathway. Oncogene. 2004;23(27):4745–4753.
   PubMed Web of Science ®Google Scholar
• Li G, Satyamoorthy K, Herlyn M. N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res. 2001;61(9):3819–3825.
   PubMed Web of Science ®Google Scholar
• Li H, Dk P, Wd F. ADH1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancer. Anticancer Drugs. 2007;18(5):563–568.
   PubMed Web of Science ®Google Scholar
• Ruzzene M, Pinna LA. Addiction to protein kinase CK2: a common denominator of diverse cancer cells? Biochim Biophys Acta. 2010;1804(3):499–504.
   PubMed Web of Science ®Google Scholar
• Pierre F, Chua PC, O’Brien SE, et al. Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer. Med Chem. 2011;54(2):635–654.
   Web of Science ®Google Scholar
• Marschke RF, Borad MJ, McFarland RW, et al. Findings from the Phase I clinical trials of CX-4945, an orally available inhibitor of CK2. J Clin Oncol. 2011;29(suppl;abstr 3087).
   Google Scholar
• Derbal-Wolfrom L, Pencreach E, Saandi T, et al. Increasing the oxygen load by treatment with myo-inositol trispyrophosphate reduces growth of colon cancer and modulates the intestine homeobox gene Cdx2. Oncogene. 2013;32(36):4313–4318.
   PubMed Web of Science ®Google Scholar
• Raykov Z, Grekova SP, Bour G, et al. Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy. Int J Cancer. 2014;134(11):2572–2582.
   PubMed Web of Science ®Google Scholar
• Basile KJ, Le K, Hartsough EJ, et al. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors. Pigment Cell Melanoma Res. 2014;27(3):479–484.
   PubMed Web of Science ®Google Scholar
• Nowsheen S, Bonner JA, Yang ES. The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy. Radiother Oncol. 2011;99(3):331–338.
   PubMed Web of Science ®Google Scholar
• Ávila-Arroyo S, Nuñez GS, García-Fernández LF, et al. Synergistic effect of trabectedin and olaparib combination regimen in breast cancer cell lines. J Breast Cancer. 2015;18(4):329–338.
   PubMed Web of Science ®Google Scholar
• Middleton MR, Friedlander P, Hamid O, et al. Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma. Ann Oncol. 2015;26(10):2173–2179.
   PubMed Web of Science ®Google Scholar
• Hussain M, Carducci MA, Slovin S, et al. Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer. Invest New Drugs. 2014;32(5):904–912.
   PubMed Web of Science ®Google Scholar
• Pishvaian MJ, Slack R, Witkiewicz A, et al. A phase II study of the PARP inhibitor ABT-888 plus temozolomide in patients with heavily pretreated, metastatic colorectal cancer. J Clin Oncol. 2011;29(suppl;abstr 3502).
   Google Scholar
• Zhao H, Ning S, Scicinski J, et al. Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity. Oncotarget. 2015;6(41):43172–43181.
   PubMed Web of Science ®Google Scholar
• Reid T, Oronsky B, Scicinski J, et al. Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study. Lancet Oncol. 2015;16(9):1133–1142.
   PubMed Web of Science ®Google Scholar
• Weitman S, Moore R, Barrera H, et al. In vitro antitumor activity of rebeccamycin analog (NSC# 655649) against pediatric solid tumors. J Pediatr Hematol Oncol. 1998;20(2):136–139.
   PubMed Web of Science ®Google Scholar
• Dowlati A, Hoppel CL, Ingalls ST, et al. Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days. J Clin Oncol. 2001;19(8):2309–2318.
   PubMed Web of Science ®Google Scholar
• Dowlati A, Posey J, Ramanathan RK, et al. Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers. Cancer Chemother Pharmacol. 2009;65(1):73–78.
   PubMed Web of Science ®Google Scholar
• Sauri T, Macarulla T, Cabrera G, et al. Comprehensive profiling of biliary tract cancers (BTC) to reveal molecular heterogeneity with implications for matched targeted therapies (MTT). J Clin Oncol. 2016;34(suppl;abstr 4085).
   Google Scholar
• Ruys AT, Groot Koerkamp B, Wiggers JK, et al. Prognostic biomarkers in patients with resected cholangiocarcinoma: a systematic review and meta-analysis. Ann Surg Oncol. 2014;21(2):487–500.
   PubMed Web of Science ®Google Scholar
• Ahn DH, Javle MM, Ahn C, et al. Next-generation sequencing (NGS) survey of biliary tract cancer (BTC) to reveal the association between tumor somatic variants and chemotherapy resistance. J Clin Oncol. 2016;34(suppl;abstr 4079).
   Google Scholar
• Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31(11):1023–1031.
   PubMed Web of Science ®Google Scholar
• Drilon A, Wang L, Arcila ME, et al. Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches. Clin Cancer Res. 2015;21(16):3631–3639.
   PubMed Web of Science ®Google Scholar